The next institute seminar takes place Wednesday 2nd of March at 12:00 in the Auditorium in the Research building, IKF, Montebello, with the following speaker:
Laxmi Silwal-Pandit – Dept. of Cancer Genetics
“Molecular responses in tumor after treatment with neoadjuvant chemotherapy with and without bevacizumab - Results from the NeoAva Study”
The NeoAva study is a phase II clinical trial where the patients with large HER2 negative breast tumors were randomized to receive neoadjuvant chemotherapy with and without antiangiogenic therapy, bevacizumab. We have performed molecular characterization of tumors at the time of diagnosis, after 12 weeks of therapy and at surgical resection. By investigating different molecular levels – copy number, methylation, mRNA, miRNA, protein and metabolites in serial tumor biopsies obtained before, during and after treatment, we provide insights into changes in the molecular architecture of the tumors in response to treatment and correlate the findings to response in a subtype-specific manner in each treatment arm.
Institute seminar organizers: